Banque Cantonale Vaudoise Purchases 1,144 Shares of HCA Healthcare, Inc. $HCA

Banque Cantonale Vaudoise boosted its position in HCA Healthcare, Inc. (NYSE:HCA) by 15.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,623 shares of the company’s stock after buying an additional 1,144 shares during the quarter. Banque Cantonale Vaudoise’s holdings in HCA Healthcare were worth $3,675,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Cerity Partners LLC increased its position in shares of HCA Healthcare by 13.1% in the third quarter. Cerity Partners LLC now owns 43,920 shares of the company’s stock valued at $18,719,000 after acquiring an additional 5,092 shares during the last quarter. Swiss National Bank boosted its holdings in shares of HCA Healthcare by 4.3% in the 2nd quarter. Swiss National Bank now owns 558,900 shares of the company’s stock valued at $214,115,000 after buying an additional 23,100 shares during the last quarter. National Pension Service lifted its stake in HCA Healthcare by 2.9% in the third quarter. National Pension Service now owns 626,585 shares of the company’s stock valued at $267,051,000 after acquiring an additional 17,531 shares during the last quarter. Savant Capital LLC lifted its stake in HCA Healthcare by 37.7% in the 3rd quarter. Savant Capital LLC now owns 4,548 shares of the company’s stock valued at $1,938,000 after purchasing an additional 1,246 shares during the last quarter. Finally, Sector Gamma AS raised its stake in HCA Healthcare by 36.0% in the third quarter. Sector Gamma AS now owns 10,883 shares of the company’s stock valued at $4,638,000 after buying an additional 2,883 shares during the period. Institutional investors own 62.73% of the company’s stock.

Analyst Ratings Changes

HCA has been the subject of several research reports. Leerink Partners raised their price target on HCA Healthcare from $507.00 to $573.00 and gave the company an “outperform” rating in a report on Wednesday, January 28th. Argus raised their price objective on shares of HCA Healthcare from $530.00 to $560.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. TD Cowen boosted their price target on HCA Healthcare from $529.00 to $561.00 and gave the company a “buy” rating in a research note on Tuesday. Truist Financial lifted their price objective on shares of HCA Healthcare from $520.00 to $546.00 and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on HCA Healthcare from $500.00 to $558.00 and gave the company a “buy” rating in a research note on Wednesday, January 28th. Sixteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $537.73.

HCA Healthcare News Summary

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: TD Cowen raised its price target on HCA to $561 and kept a Buy rating, signaling continued analyst confidence and suggesting upside versus the current share level. This type of analyst action often supports buying interest. Article Title
• Positive Sentiment: HCA system was cleared to build a freestanding emergency room despite community pushback — a win for local expansion plans and potential incremental revenue/volume growth in the market where it will operate. Article Title
• Positive Sentiment: Zacks published pieces highlighting HCA as a momentum and value stock and as a name with earnings growth/price strength — favorable retail/quant narratives that can attract buyers. (Multiple Zacks items.) Momentum Article
• Neutral Sentiment: Management presented at the Barclays 28th Annual Global Healthcare Conference — transcripts provide detail on strategy, capital allocation and growth initiatives but offered no headline surprises that would immediately re-rate the stock. Barclays Transcript
• Neutral Sentiment: HCA also presented at the Leerink Global Healthcare Conference — additional management commentary (transcript) that reinforces the same operational and growth themes but adds incremental detail rather than new catalysts. Leerink Transcript
• Neutral Sentiment: HCA’s CIO discussed the importance of “operational quiet” for digital transformation — an execution-focused piece that underlines IT/digital investment discipline but is more about long-term efficiency than an immediate earnings shock. CIO Article

HCA Healthcare Price Performance

NYSE HCA opened at $537.78 on Wednesday. HCA Healthcare, Inc. has a fifty-two week low of $310.18 and a fifty-two week high of $552.90. The business has a fifty day moving average price of $503.07 and a two-hundred day moving average price of $467.72. The stock has a market capitalization of $120.26 billion, a PE ratio of 18.95, a PEG ratio of 1.67 and a beta of 1.34.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, topping analysts’ consensus estimates of $7.37 by $0.64. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The company had revenue of $19.51 billion during the quarter, compared to analysts’ expectations of $19.67 billion. During the same quarter in the previous year, the firm earned $6.22 EPS. HCA Healthcare’s revenue was up 6.7% on a year-over-year basis. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, sell-side analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 17th will be given a dividend of $0.78 per share. The ex-dividend date is Tuesday, March 17th. This represents a $3.12 dividend on an annualized basis and a yield of 0.6%. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.72. HCA Healthcare’s dividend payout ratio is currently 10.99%.

Insider Activity at HCA Healthcare

In other HCA Healthcare news, SVP Jennifer Berres sold 8,020 shares of the stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $514.58, for a total value of $4,126,931.60. Following the completion of the transaction, the senior vice president directly owned 11,993 shares in the company, valued at approximately $6,171,357.94. This trade represents a 40.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael R. Mcalevey sold 1,694 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $533.37, for a total value of $903,528.78. Following the completion of the transaction, the executive vice president directly owned 8,853 shares of the company’s stock, valued at $4,721,924.61. This represents a 16.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 15,214 shares of company stock worth $7,797,595. Corporate insiders own 1.30% of the company’s stock.

HCA Healthcare Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.